Our top pick for
Radius Health, Inc is a drug manufacturers—specialty & generic business based in the US. Radius Health shares (RDUS) are listed on the NASDAQ and all prices are listed in US Dollars. Radius Health employs 383 staff and has a trailing 12-month revenue of around USD$231.5 million.
|Latest market close||USD$15.92|
|52-week range||USD$10.151 - USD$23.8798|
|50-day moving average||USD$13.7357|
|200-day moving average||USD$13.0404|
|Wall St. target price||USD$20.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.7|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-16)||15.92|
|1 month (2020-10-23)||15.53%|
|3 months (2020-08-24)||34.80%|
|6 months (2020-05-22)||25.16%|
|1 year (2019-11-22)||-31.97%|
|2 years (2018-11-23)||15.92|
|3 years (2017-11-24)||-44.30%|
|5 years (2015-11-24)||-74.03%|
|Revenue TTM||USD$231.5 million|
|Gross profit TTM||USD$158 million|
|Return on assets TTM||-25.84%|
|Return on equity TTM||0%|
|Market capitalisation||USD$727.1 million|
TTM: trailing 12 months
There are currently 7.4 million Radius Health shares held short by investors – that's known as Radius Health's "short interest". This figure is 1.9% up from 7.3 million last month.
There are a few different ways that this level of interest in shorting Radius Health shares can be evaluated.
Radius Health's "short interest ratio" (SIR) is the quantity of Radius Health shares currently shorted divided by the average quantity of Radius Health shares traded daily (recently around 373764.39393939). Radius Health's SIR currently stands at 19.8. In other words for every 100,000 Radius Health shares traded daily on the market, roughly 19800 shares are currently held short.
However Radius Health's short interest can also be evaluated against the total number of Radius Health shares, or, against the total number of tradable Radius Health shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Radius Health's short interest could be expressed as 0.16% of the outstanding shares (for every 100,000 Radius Health shares in existence, roughly 160 shares are currently held short) or 0.2193% of the tradable shares (for every 100,000 tradable Radius Health shares, roughly 219 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Radius Health.
Find out more about how you can short Radius Health stock.
We're not expecting Radius Health to pay a dividend over the next 12 months.
Radius Health's shares were split on a 1:2 basis on 24 April 2014. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Radius Health shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for Radius Health shares which in turn could have impacted Radius Health's share price.
Over the last 12 months, Radius Health's shares have ranged in value from as little as $10.151 up to $23.8798. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Radius Health's is 1.0789. This would suggest that Radius Health's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS, an anabolic agent for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in phase 3 clinical study for the treatment of osteoporosis in men; abaloparatide transdermal patch, a short-wear-time patch, that is in phase 3 clinical study to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in phase 3 clinical study for the treatment of hormone receptor-positive breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator, which is in phase 1A clinical study to treat metastatic breast cancer. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; Guardant Health, Inc.; and Teijin Limited. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Steps to owning and managing SELF, with 24-hour and historical pricing before you buy.
Steps to owning and managing GLP, with 24-hour and historical pricing before you buy.
Steps to owning and managing FRGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXFO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ESRT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PLOW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FOF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing CGNX, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.